Aurora Cannabis Announces Market Launch Of Softgel Capsules (NYSE: ACB) (TSX: ACB) – RICH TV LIVE – DECEMBER 3, 2018 – BREAKING NEWS – AURORA CANNABIS LITERALLY WENT UP WHILE I WAS FILMING – EDMONTON, Dec. 3, 2018 /CNW/ – Aurora Cannabis Inc. (“Aurora” or the “Company”) (NYSE:ACB) (TSX:ACB.TO) (Frankfurt: 21P; WKN: A1C4WM) announced today that, further to its October 17, 2018 announcement that it had received a sales license from Health Canada permitting the sale of cannabis softgel capsules, the Company has commenced shipments for both the Canadian medical and adult-use markets. Aurora expects to commence exports to international markets in early 2019.
At scale, the Company anticipates that softgel production at its state-of-the-art Aurora Vie facility in Quebec will reach at least 1.4 million capsules per week. Aurora intends to make this high-volume, high-margin, smoke-free, product available to all of its domestic and international target markets over time where legally possible.
Aurora’s softgel capsules are produced to pharmaceutical-grade standards at Aurora Vie, in collaboration with leading softgel manufacturer Capcium Inc. (“Capcium”), in which Aurora holds a 19.99% ownership interest. The Company will initially launch the capsules to the medical cannabis market in Canada as well as the adult-use market in British Columbia with additional provincial markets to follow.
The Company is initially launching four softgel product types, each available in bottles of 30 capsules, priced at $45 per bottle. The small, easy to digest soft gelatin capsules are colour-coded to distinguish between the different varieties for the protection of public health and safety. They are believed to the smallest cannabis capsules on the market. Aurora’s softgels provide a dosage-controlled format that medical practitioners and consumers around the world need to facilitate more precise administration.
For the medical market, Aurora is launching three product types:
Aurora Indica Softgels: 8-10 mg/pill of THC
Aurora Sativa Softgels: 8-10 mg/pill of THC?
Aurora CBD Softgels: 8-10 mg/pill of CBD
For the BC consumer market, one product type will be available initially:
Aurora Liquid Gels: 8-10 mg/pill of CBD, targeted at the non-prescription wellness segment of the market
Additional product types and potencies will be made available in the coming months including softgel capsules that contain 5mg THC, 20mg CBD and 1:1 (5gm CBD and 5mg THC), plus softgels that employ a range of functional carrier oils.
Subscribe – https://www.youtube.com/c/RICHTVLIVE
Visit – http://www.richtvlive.com/ a one-stop shop for cryptocurrency, stocks, sports, travel and trending topics. #richtvlive #auroracannabis #education
Join the RICH TV LIVE FREE Social Media Community – Download the Amino app on your phone or computer and follow the link – https://aminoapps.com/c/RICHTVLIVE/home/
Join the Conversation get the RICH TV LIVE app at Google Play – https://play.google.com/store/apps/details?id=com.app.richtvlive
iPhone App Store – https://itunes.apple.com/us/app/richtvlive/id1212158240?Is=1&mt=8
Popular Uploads – https://goo.gl/tbvXGg
Most Recent Upload – https://goo.gl/unKXBy
YouTube Channel Page – https://goo.gl/yUdG7w
Subscribe – https://goo.gl/q2tLnn
Rich TV Live Playlist – https://goo.gl/e116JF
YouTube support Tubebuddy – https://www.tubebuddy.com/RICHTVLIVE
Rich TV’s company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in Rich TV reports company profiles or other investor relations materials and presentations are subject to change. Rich TV and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
Investing is inherently risky. Rich TV is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission (“SEC”) at www.sec.gov.